)
Visual
test
Mesoblast
Mesoblast (MSB) investor relations material
Mesoblast Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary28 Jan, 2026
Executive summary
RyoncilⓇ net revenues reached US$30 million for the quarter ended December 31, 2025, a 60% increase over the prior quarter, driven by strong sales and expanded clinical use.
A new non-dilutive US$125 million credit line was established at a lower fixed interest rate, enhancing financial flexibility for strategic initiatives.
RyoncilⓇ remains the only FDA-approved MSC therapy for pediatric SR-aGvHD, with positive real-world outcomes and ongoing label expansion efforts.
Financial highlights
Gross sales for RyoncilⓇ were US$35 million, with net revenues of US$30 million, up 60% sequentially from the previous quarter.
Cash at quarter end was US$130 million; net operating cash spend for the quarter was US$16 million.
Net cash from operating activities for the quarter was negative US$15.6 million.
Estimated quarters of funding available is 11.6, based on current cash and financing facilities.
Outlook and guidance
Net cash spend is expected to decrease over the remainder of the fiscal period due to projected revenue receipts and tight expense control.
Pivotal trial for RyoncilⓇ in adults with SR-aGvHD to commence site enrollment this quarter, targeting a population three times larger than pediatric.
Confirmatory Phase 3 trial for rexlemestrocel-L in chronic low back pain is actively recruiting and expected to complete enrollment in three months.
Rexlemestrocel-L BLA filing strategy
New credit line's impact on strategic flexibility
Ryoncil® adult market penetration strategy
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- RBX
Revenue up 29.7%, profit up 34.7%, and order book at R24.5bn, supporting a positive outlook. - ABFRL
Q3 FY26 net losses persisted despite revenue growth, amid restructuring and regulatory costs. - TRACXN
Q3 FY26 revenue was INR 21 crore with a net loss, but customer and account growth remained strong. - DWNI
Stabilized real estate values, strong rental demand, and major transactions drive results. - OCUL
Net loss widened in 2025 as clinical trials advanced, but cash runway extends into 2028. - VARROC
Revenue and EBITDA margin rose YoY, but exceptional costs and legal disputes weighed on profit. - PRIC
Record Q4 order intake, new contracts, and improved cash flow despite lower sales and profits. - ENSI
Record revenue growth, positive EBITDA, and strong outlook with cash flow positivity expected by end-2026. - DWNIStable rental growth, Care segment sale, and positive 2025 outlook despite lower EBT.
- JUBLINGREA
Volume growth in specialty and nutrition offset pricing headwinds; net debt down 20% YoY.
Next Mesoblast earnings date
H1 202625 Feb, 2026
Mesoblast
Next Mesoblast earnings date
H1 202625 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Mesoblast Limited is an Australian biotechnology company that develops cellular medicines based on mesenchymal lineage cells. The company’s pipeline targets inflammatory and cardiovascular diseases, with therapies in various stages of clinical development. Its operations include research, regulatory affairs, and strategic licensing. Mesoblast Limited is headquartered in Melbourne, Australia, and its shares are listed on the ASX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage